{"protocolSection":{"identificationModule":{"nctId":"NCT04631055","orgStudyIdInfo":{"id":"ACOART intracranial de novo"},"organization":{"fullName":"Acotec Scientific Co., Ltd","class":"INDUSTRY"},"briefTitle":"ACOART Intracranial de Novo:DCB in the Treatment of Symptomatic Intracranial Atherosclerotic de Novo Stenosis","officialTitle":"A Prospective, Multicenter, Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Intracranial Drug-coated Balloon Catheters in the Treatment of Symptomatic Intracranial Atherosclerotic de Novo Stenosis"},"statusModule":{"statusVerifiedDate":"2023-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-06-04","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-04-10","type":"ACTUAL"},"completionDateStruct":{"date":"2023-04-13","type":"ACTUAL"},"studyFirstSubmitDate":"2020-11-03","studyFirstSubmitQcDate":"2020-11-10","studyFirstPostDateStruct":{"date":"2020-11-17","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-10-19","lastUpdatePostDateStruct":{"date":"2023-10-23","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Acotec Scientific Co., Ltd","class":"INDUSTRY"},"collaborators":[{"name":"Beijing Tiantan Hospital","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of the RCT trial is to determine whether DCB is not inferior to stent in treating intracranial de novo stenosis.","detailedDescription":"This trial is a prospective, multi-center, 1:1 randomized using paclitaxel coated balloon versus stent to treat intracranial stenosis of 70-99% degree. And primary endpoint is angiographic restenosis at 6 months post-procedure."},"conditionsModule":{"conditions":["Intracranial Atherosclerosis","Stroke"],"keywords":["Intracranial Atherosclerosis","Stroke","drug coated balloon"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":180,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"DCB group","type":"EXPERIMENTAL","description":"use intracranial drug coated balloon catheter made by Acotec Scientific Co.,Ltd.","interventionNames":["Device: drug coated balloon"]},{"label":"Stent group","type":"ACTIVE_COMPARATOR","description":"use the Intracranial Stent System made by MicroPort.","interventionNames":["Device: stent system"]}],"interventions":[{"type":"DEVICE","name":"drug coated balloon","description":"paclitaxel coated balloon catheter for intracranial PTA treatment","armGroupLabels":["DCB group"]},{"type":"DEVICE","name":"stent system","description":"The Intracranial Stent System comprises of a balloon expandable stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.The product, APOLLO™ stent system, has the indication of endovascular treatment for intracranial stenosis approved by NMPA.","armGroupLabels":["Stent group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Angiographic restenosis of the target lesion","description":"angiographic restenosis measured by WASID ( Warfarin-Aspirin Symptomatic Intracranial Disease) method in core-lab","timeFrame":"6 months post-procedure"}],"secondaryOutcomes":[{"measure":"device success rate","description":"DCB: The balloon dilatation catheter was able to reach the treated lesion, successfully dilated without rupture, and successfully retreated.\n\nStent: The stent enables successful arrival of the lesion and subsequent release of the stent delivery system for successful withdrawal.","timeFrame":"during procedure"},{"measure":"target vessel stroke or death event","description":"Stroke (bleeding and ischemia) or death related to target vessels within 30 days postoperatively.","timeFrame":"within 30 days post-procedure"},{"measure":"target vessel ischemia stroke event","description":"The incidence of recurrent ischemic stroke in the target vessel supply area 31 days to 6 months postoperatively","timeFrame":"between 31 days and 6 months post-procedure"},{"measure":"Cerebral parenchyma hemorrhage, subarachnoid hemorrhage or intraventricular hemorrhage events","description":"Any parenchymal hemorrhage, subarachnoid hemorrhage, or intraventricular hemorrhage 31 days to 6 months postoperatively","timeFrame":"between 31 days and 6 months post-procedure"},{"measure":"target vessel death event","description":"Target-vessel related death 31 days to 6 months postoperatively","timeFrame":"between 31 days and 6 months post-procedure"},{"measure":"transient ischemic attack event","description":"transient ischemic attack event transient ischemic attack event","timeFrame":"at 6 months post-procedure"},{"measure":"National Institutes of Health Stroke Scale score","description":"National Institutes of Health Stroke Scale score at 6 months post-procedure(0-42,higher scores mean a worse outcome)","timeFrame":"at 6 months post-procedure"},{"measure":"Modified Rankin Scale score","description":"Modified Rankin Scale score at 6 months post-procedure(0-5,higher scores mean a worse outcome)","timeFrame":"at 6 months post-procedure"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 18 to 80 years of age;\n* Patients with symptomatic intracranial atherosclerotic stenosis;\n* Patients with intracranial arterial de novo stenosis confirmed by digital subtraction angiography (DSA);\n* Confirmed by DSA，the diameter of the target vessel is between 2.5mm-4.5mm ; according to WASID method, the degree of stenosis of the target lesion is 70%-99%;\n* Baseline mRS score ≤2;\n* Voluntarily participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients with stroke within 2 weeks before procedure;\n* Patients with stroke caused by perforating artery occlusion;\n* Any history of brain parenchymal or other intracranial subarachnoid, subdural or extradural hemorrhage in the past 30 days;\n* Those who have received thrombolysis within 24 hours before procedure;\n* Deterioration of neurological function within 24 hours before procedure (defined as NIHSS score increased by ≥ 4 points over the baseline);\n* The vascular path showed in angiography is so tortuous that it is difficult to advance catheters to the target lesion or retrieve;\n* Lesions that investigators believe are not suitable for stenting;\n* Patients with thrombus in target vessel;\n* In addition to the target lesion, there are still other de novo lesion or ISR lesion with more than 70% diameter stenosis in intracranial arteries that need to be treated at the same time;\n* After endovascular treatment of the target lesion, there is still a stenosis of more than 50% in the main blood supplying artery or an obstructive lesion in the distal vessel of target lesion;\n* Major surgery (including open femoral artery, aortic or carotid artery surgery) within the past 30 days or planned within 90 days;\n* Patients with renal artery, iliac artery, and coronary artery requiring simultaneous intervention;\n* Combined with intracranial tumor, aneurysm or intracranial arteriovenous malformation;\n* Intracranial artery stenosis caused by non-atherosclerotic lesions, including: arterial dissection, moya-moya disease, vasculitis disease, herpes zoster, varicella-zoster or other viral vascular diseases, neurosyphilis, any Other intracranial infections, any intracranial stenosis related to cerebrospinal fluid cells, radiation-induced vascular disease, fibromuscular dysplasia, sickle cell disease, neurofibromatosis, central nervous system benign vascular disease, postpartum vascular disease, suspected Vasospasm, suspicious embolism recanalization, etc.;\n* Cardiac stroke or potential cardiogenic thromboembolism, with any of the following cardiogenic embolism causes: chronic or paroxysmal atrial fibrillation, mitral valve stenosis, mechanical valves, endocarditis, intracardiac thrombus or implant, dilated cardiomyopathy, spontaneous acoustic imaging of the left atrium;\n* Patients with myocardial infarction within 6 weeks before procedure;\n* Those who cannot tolerate general anesthesia due to insufficiency of important organs such as heart and lungs;\n* Patients with known severe hepatic and renal dysfunction;\n* Patients with hemoglobin\\<100g/L, platelet count\\<100×1,000,000,000/L, INR\\>1.5 or there are uncorrectable factors leading to bleeding(if there are multiple checks, the last one shall prevail);\n* Patients who cannot receive dual antiplatelet therapy due to existing diseases or are tolerant to dual antiplatelet therapy confirmed by relevant test;\n* Patients with known severe allergies or contraindications to heparin, paclitaxel, contrast agents and other related intravascular treatment drugs;\n* Current alcohol or drug abuse, uncontrolled severe hypertension (systolic blood pressure\\>180mmHg or diastolic blood pressure\\>110mmHg);\n* Life expectancy \\<1 year;\n* Pregnant or lactating women;\n* Patients who cannot complete the follow-up due to cognitive, emotional or mental illness;\n* Patients who are participating in other drug/device clinical trials and have not completed all follow-ups required by the programmer;\n* According to the judgement of the investigator, other situations that are not suitable for enrollment.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Zhongrong Miao, MD","affiliation":"Beijing Tiantan Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Beijing Tiantan Hospital","city":"Beijing","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Nanyang City Central Hospital","city":"Nanyang","country":"China","geoPoint":{"lat":32.99472,"lon":112.53278}},{"facility":"Shanxi Cardiovascular Hospital","city":"Taiyuan","country":"China","geoPoint":{"lat":37.86944,"lon":112.56028}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000002537","term":"Intracranial Arteriosclerosis"},{"id":"D000050197","term":"Atherosclerosis"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001161","term":"Arteriosclerosis"},{"id":"D000001157","term":"Arterial Occlusive Diseases"},{"id":"D000020765","term":"Intracranial Arterial Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M25878","name":"Atherosclerosis","asFound":"Atherosclerosis","relevance":"HIGH"},{"id":"M6165","name":"Constriction, Pathologic","relevance":"LOW"},{"id":"M5476","name":"Intracranial Arteriosclerosis","asFound":"Intracranial Atherosclerosis","relevance":"HIGH"},{"id":"M4159","name":"Arteriosclerosis","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M4155","name":"Arterial Occlusive Diseases","relevance":"LOW"},{"id":"M22211","name":"Intracranial Arterial Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M19227","name":"Paclitaxel","relevance":"LOW"},{"id":"M231","name":"Albumin-Bound Paclitaxel","relevance":"LOW"}],"browseBranches":[{"abbrev":"ANeo","name":"Antineoplastic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}